Infliximab

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype = mab

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type=mab | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data=mabxi/o | _mab_vaccine_data=Tumor necrosis factors (TNF) | _mab_other_data=6428991216941987 | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.coma604023Infliximab <ref name="Drugs.com pregnancy">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>CIntravenous, subcutaneousRemicadeL04 | _legal_data=S4/ Schedule D<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="CA 2016 Highlights">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>Rx-only<ref name="Remicade EPAR" /><ref name="Flixabi EPAR" /><ref name="Remsima EPAR" /><ref name="Inflectra EPAR" /><ref name="Zessly EPAR" />Rx-onlyPOM<ref name="Remicade FDA label">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>Rx-only

| _other_data=

| _image_0_or_2 = Infliximab_structure2.jpg | _image_LR =

| _datapage = Infliximab (data page) | _vaccine_target={{#ifeq:mab | vaccine | Tumor necrosis factors (TNF) | _type_not_vaccine }} | _legal_all=S4Rx-onlyPOMRx-onlyRx-only | _ATC_prefix_supplemental=L04 | _has_EMA_link = | CAS_number=170277-31-3 | PubChem= | ChemSpiderID=none | ChEBI= | ChEMBL=1201581 | DrugBank=DB00065 | KEGG=D02598 | _hasInChI_or_Key={{#if: |yes}} | UNII=B72HH48FLU | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields= |verifiedrevid=458271995}}

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.<ref name=AHFS2019/> It is given by slow injection into a vein, typically at six- to eight-week intervals.<ref name=AHFS2019/>

Common side effects include infections, acute infusion reactions, and abdominal pain.<ref name=AHFS2019/> Infliximab is a chimeric monoclonal antibody biologic. It seems to work by binding to and neutralizing TNF-α, preventing it from interacting with its receptors on the cell.<ref name=AHFS2019/> TNF-α is a chemical messenger (cytokine) and a key part of the autoimmune reaction.

Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".<ref>Template:Cite journal</ref>Template:Medical citation needed

Infliximab was approved for medical use in the United States in 1998,<ref name=AHFS2019>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and in the European Union in August 1999.<ref name="Remicade EPAR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).<ref name="Renflexis FDA approval" /><ref name="Ixifi FDA approval" /><ref name="Avsola FDA approval" /> It is on the World Health Organization's List of Essential Medicines.<ref name="WHO22nd">Template:Cite book</ref> Template:TOC limit

Medical uses

Crohn's disease

Three phenotypes, or categories of disease, are present in Crohn's disease: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes fistulae or abnormal connections of the bowel), and inflammatory disease (which primarily causes inflammation).<ref name=phenotypes>Template:Cite journal</ref>

Fistulizing disease

Infliximab was first used for closure of fistulae in Crohn's disease in 1999. In a 94-patient, phase II clinical trial, the researchers showed infliximab was effective in closing fistulae between the skin and bowel in 56–68% of patients.<ref name=Present>Template:Cite journal</ref> A large, 296-patient Phase III clinical trial called the ACCENT 2 trial showed infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the three initial doses of infliximab having a fistula response after 14 weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received placebo therapy. This final trial resulted in the FDA approval of the drug to treat fistulizing disease.<ref name=ACCENT2>Template:Cite journal</ref>

Inflammatory disease

Infliximab has been used to induce and maintain remission in inflammatory Crohn's disease. The ACCENT 1 trial, a large, multicentre trial, found 39–45% of patients treated with infliximab, who had an initial response to it, maintained remission after 30 weeks, compared with 21% who received placebo treatment. It also showed a mean maintenance of remission from 38 to 54 weeks compared with 21 weeks for patients who received placebo treatment.<ref name=ACCENT1>Template:Cite journal</ref>

Crohn's patients have flares of their disease between periods of disease quiescence. Severe flares are usually treated with steroid medications to obtain remission, but steroids have many undesirable side effects, so some gastroenterologists are now advocating the use of infliximab as the first drug to try to get patients into remission. This has been called the top-down approach to treatment.<ref name=topdown>Template:Cite journal</ref>

Ulcerative colitis

Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.<ref name=ACT>Template:Cite journal</ref>

Psoriatic arthritis

In psoriatic arthritis (PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of cyclosporine and infliximab. Based on studies in AS, the results suggest infliximab, etanercept, and adalimumab have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of enthesitis than traditional agents. Results suggest infliximab is effective for the treatment of dactylitis in PsA.<ref>Template:Cite journal</ref>

Other

It was approved for treating ankylosing spondylitis,<ref name="Maxwell">Template:Cite journal</ref> psoriatic arthritis, psoriasis, rheumatoid arthritis.<ref>Template:Cite journal</ref>

Infliximab is also prescribed (out of indication) for the treatment of Behçet's disease.<ref>Template:Cite journal</ref>

Infliximab is the most frequently used biological agent in treating relapsing polychondritis.<ref name="Relapsing polychondritis">Template:Cite journal</ref> Half of the patients saw benefit from this treatment, and a few other patients experienced infections that in some cases lead to death.<ref name="Relapsing polychondritis"/><ref>Template:Cite journal</ref>

There have been numerous case reports of the efficacy of infliximab in various inflammatory skin conditions diseases; the FDA approved infliximab for chronic severe plaque psoriasis in adults in September 2006.<ref>Template:Cite journal</ref>

Infliximab has been used off-label in treating refractory sarcoidosis, where other treatments have not been effective.<ref>Template:Cite journal</ref>

Infliximab has been tested in chronic obstructive pulmonary disease (COPD) but there was no evidence of benefit with the possibility of harm.<ref>Template:Cite journal</ref>

Infliximab is indicated for steroid refractory checkpoint inhibitor induced colitis, at a dose of 5 to 10 mg/kg.<ref name=Brahmer>Template:Cite journal</ref>

Infliximab has been found to be a safe alternative treatment to a second dose of IVIG for Kawasaki Disease resistant to initial IVIG therapy, showing better outcomes in fever resolution and fewer severe adverse effects such as hemolytic anemia.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Adverse effects

Infliximab has adverse effects, some life-threatening, common to drugs in the class of TNF inhibiting immunosuppressants (which also includes etanercept (Enbrel) and adalimumab (Humira)). Some of the most severe are:

• serious infections
• reactivation of hepatitis B
• reactivation of tuberculosis<ref>Template:Cite journal</ref>
• lethal hepatosplenic T-cell lymphoma (generally only when combined with 6-mercaptopurine)
• drug-induced lupus
• demyelinating central nervous system disorders
• psoriasis and psoriasiform skin lesions
• new-onset vitiligo

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }} Template:PD-notice</ref>

Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with methotrexate (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis<ref>Template:Cite journal</ref> and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease.<ref name="ACCENT1"/> The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks. Infliximab was studied in monotherapy (without concomitant immunosuppressants such as methotrexate or azathioprine) in psoriasis, psoriatic arthritis, and ankylosing spondylitis.<ref name="Maxwell" />

Pharmacology

Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions.<ref name="Akiho1">Template:Cite journal</ref> It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment.<ref name="Akiho1"/>

Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. Infliximab and adalimumab (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-, transmembrane-, and receptor-bound) of TNF-α.<ref>Template:Cite journal</ref> Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF-α.<ref>Etanercept product labeling</ref> Additionally, the anti-TNF antibodies adalimumab and infliximab have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability.<ref>Etanercept, Adalimumab and Infliximab product labeling</ref>

Other monoclonal antibodies targeting TNF-α are golimumab, adalimumab, and certolizumab pegol. Etanercept also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).<ref>Template:Cite journal</ref>

History

The importance of TNF in the development of rheumatoid arthritis was originally demonstrated by George Kollias and colleagues in proof of principle studies in transgenic animal models.<ref name="pmid1721867">Template:Cite journal</ref><ref name="pmid26008591">Template:Cite journal</ref>

Infliximab was developed by Junming Le (b. 1940) and Jan Vilček (b. 1933) at New York University School of Medicine and in collaboration with Centocor (now Janssen Biotech, Inc.).<ref>Template:Cite journal</ref>

Society and culture

Marketing

Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the United States, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere.<ref name="JNJ_20071106_141812">Template:Cite press release</ref>

Biosimilars

In June 2013, two biosimilar versions (Inflectra and Remsima) were submitted for approval in the European Union, by Hospira and Celltrion Healthcare respectively.<ref name=george2013>Template:Cite news</ref> Both had a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for sale in the European Union (EU).<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by September 2013.<ref>Template:Cite news</ref><ref name="Remsima EPAR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="Inflectra EPAR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Inflectra was approved for use in the European Union in September 2013,<ref name="Inflectra EPAR" /> and Remsima was approved for use in the European Union in October 2013.<ref name="Remsima EPAR" />

In Japan, Celltrion received marketing authorization for Remsima from Japan's Ministry of Health, Labour and Welfare (MHLW) in July 2014.Template:Citation needed

In India, Epirus Biopharmaceuticals obtained approval to produce biosimilar infliximab under the brand name "Infimab" (trail name BOW015).<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The US Food and Drug Administration (FDA) approved Celltrion/Hospira/Pfizer's Inflectra (infliximab-dyyb) in April 2016.<ref name="FDA PR 20191206">Template:Cite press release Template:PD-notice</ref><ref name="Inflectra FDA approval">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

The FDA approved Samsung Bioepis Co., Ltd.'s Renflexis (infliximab-abda) in April 2017.<ref name="Renflexis FDA approval">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Biogen released another biosimilar, Flixabi, which was approved in Germany, the UK, and the Netherlands.<ref name=biib>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Flixabi was approved for use in the European Union in May 2016.<ref name="Flixabi EPAR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In December 2017, Ixifi (infliximab-qbtx) was approved in the United States.<ref name="Ixifi FDA approval">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Zessly was approved for use in the European Union in May 2018.<ref name="Zessly EPAR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In December 2019, Avsola (infliximab-axxq) was approved in the United States.<ref name="Avsola FDA approval">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Avsola was approved for medical use in Canada in March 2020.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In December 2021, Ixifi was approved for medical use in Canada.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Availability/affordability

Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> so must be reconstituted and administered by a health care professional, usually in a hospital or office setting.<ref name="JNJ_20071106_141812" /> For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages.<ref name="JNJ_20071106_141812" />

In the UK, infliximab is available from the NHS for Crohn's disease treatment provided three criteria are met.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since February 2015, it is also approved for the treatment of ulcerative colitis where other treatments have not worked.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

In Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013."<ref>JNJ annual report, downloaded 22 April 2014. {{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Zymfentra was approved for medical use in the United States in October 2023.<ref name="Zymfentra PR">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

External links

• Template:Commonscatinline